<DOC>
	<DOCNO>NCT00000653</DOCNO>
	<brief_summary>To evaluate compare long-term ( 48-177 week ) safety , tolerance , efficacy two dos zalcitabine ( dideoxycytidine ; ddC ) take orally every 8 hour child symptomatic HIV infection one following : intolerance zidovudine ( AZT ) ( development toxicity prolong AZT therapy ) , demonstrate disease progression 6 month AZT therapy , OR AZT intolerance disease progression 6 month AZT therapy . As useful AZT appear treatment patient infected HIV , associate significant toxicity patient , prevent ultimate progression AIDS eventual mortality . Thus , clear need new antiretroviral drug , ddC one promising agent .</brief_summary>
	<brief_title>A Trial Two Doses 2',3'-Dideoxycytidine ( ddC ) Treatment Children With Symptomatic HIV Infection Who Are Intolerant AZT and/or Who Show Progressive Disease While AZT</brief_title>
	<detailed_description>As useful AZT appear treatment patient infected HIV , associate significant toxicity patient , prevent ultimate progression AIDS eventual mortality . Thus , clear need new antiretroviral drug , ddC one promising agent . Patients receive oral ddC 48 177 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Procrit . Amphotericin B ( 1 mg/kg 5 days/week ) . Prophylaxis treatment per ACTG recommendation Pneumocystis carinii pneumonia . Acyclovir ( 1000 mg/day PO ; &gt; 1000 mg/day PO IV dose , suggest interrupt ddC ) . Ketoconazole ( 10 mg/kg/day ) . Nystatin . Aspirin , acetaminophen , sedative , barbiturate ( 72 hour ) . Isoniazid ( INH ) , evidence peripheral neuropathy entry . Children receive pyridoxine , 25 50 mg/day avoid possible INHassociated neuropathy . Trimethoprim / sulfamethoxazole ( T/S ) . Immunoglobulin therapy . Aerosolized pentamidine . Drugs little nephro , hepato , cytotoxicity patient take tolerate well ongoing condition . Concurrent Treatment : Allowed : Immunoglobulin therapy . Nutritional support ( child waste syndrome and/or malnutritional ) include hyperalimentation ( TPN ) dietary supplement . AMENDED : Patients enrol ACTG 051 may participate ACTG 138 show intolerance AZT show disease progression 6 month AZT therapy meet entry criterion study . ORIGINAL design : Patients enrol ACTG protocols 051 128 must meet study end point meet protocol definition permanently zidovudine ( AZT ) enrol protocol . Patients must follow : Absence acute opportunistic infection time entry . However , patient successfully treat opportunistic infection remain stable 2 week treatment , patient allow enter study . Children receive maintenance therapy &gt; 4 week eligible . Parent guardian available give write informed consent . Allowed time study entry : Prophylaxis treatment per ACTG recommendation , Pneumocystis carinii pneumonia ( PCP ) . Immunoglobulin therapy . Prior Medication : AMENDED : AZT ddI study entry , antiretrovirals 4 week study entry Allowed : Zidovudine ( AZT ) within 4 week entry . Dideoxyinosine ( ddI ) within 43 week entry peripheral neuropathy observe receive ddI . Other toxicity observe ddI must resolve level 2 well patient begin treatment ddC . Vitamin , folate , iron supplement . Exclusion Criteria Coexisting Condition : AMENDED : 042591 Additional exclude symptoms condition : Symptomatic cardiomyopathy . Seizures well control ongoing anticonvulsant therapy . Active malignancy require concomitant chemotherapy . Symptomatic pancreatitis . Grade I great peripheral neuropathy . Receiving concomitant zidovudine ( AZT ) . Patients follow condition symptom exclude : Acute bacterial infection require IV oral antibiotic treatment time entry . Known hypersensitivity dideoxycytidine ( ddC ) . Concurrent Medication : Excluded : Other antiviral agent , biological modifier , investigational medication . Drugs potential cause peripheral neuropathy , include chloramphenicol , iodoquinol , phenytoin , ethionamide , gold , ribavirin , vincristine , cisplatin , dapsone , disulfiram , glutethimide , hydralazine , metronidazole , nitrofurantoin . Patients follow exclude : Acute bacterial infection require IV oral antibiotic treatment time entry . Known hypersensitivity dideoxycytidine ( ddC ) . Active opportunistic infection require treatment exclude concomitant medication . Prior Medication : Excluded : Antiretroviral agent ( zidovudine ( AZT ) didanosine ( ddI ) ) within 4 week entry . Immunomodulating agent interferon , isoprinosine , interleukin2 within 2 week entry . Any experimental therapy , drug cause prolong neutropenia , significant nephrotoxicity , peripheral neuropathy within 1 week entry .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>